Joanne Miller
Family · Tuscaloosa, ALNPI 1740514926
Payments from drug & device makers
Across 79 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$186
- AstraZeneca$150
- Deciphera Pharmaceuticals Inc.$138
- Pfizer$90
- Pharmacyclics LLC, An Abbvie Company$89
- Daiichi Sankyo Inc.$88
- plus $715 from 19 others
What the payments were for
- Food & beverage$1,456100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $186 |
| AstraZeneca | 9 | $150 |
| Deciphera Pharmaceuticals Inc. | 7 | $138 |
| Pfizer | 5 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $89 |
| Daiichi Sankyo Inc. | 4 | $88 |
| Array Biopharma Inc | 3 | $76 |
| AbbVie | 5 | $76 |
| Coherus Oncology, Inc. | 4 | $67 |
| Merck | 3 | $61 |
| Johnson & Johnson | 4 | $58 |
| GSK | 3 | $58 |
| Pharmaessentia USA Corporation | 2 | $44 |
| Astellas Pharma US Inc | 2 | $35 |
| Incyte Corporation | 2 | $33 |
| Sanofi | 2 | $31 |
| Bristol Myers Squibb | 1 | $30 |
| EUSA Pharma (US) LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Sobi, Inc | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
How this compares
$1,456 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 18 | $893 |
| Letrozole | 15 | $612 |
| Anastrozole | 14 | $405 |
| Levothyroxine Sodium | 15 | $153 |
Paid to pharmacies, not to this prescriber.
Other family in Tuscaloosa
- Justin SimpsonTuscaloosa$43K
- Ashley StinesTuscaloosa$29K
- Lauren KyzarTuscaloosa$17K
- Dee GuyTuscaloosa$14K
- Haley TippsTuscaloosa$14K
- Jeremy KelleyTuscaloosa$13K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.